Scientific Programme

Programme-at-a-Glance

THURSDAY 7 JUNE

FRIDAY 8 JUNE

SATURDAY 9 JUNE

09:30 - 12:30

07:30 - 08:30

07:30 - 08:30

Ultrasound and Fibroscan Workshop 1

Early Morning Workshop 1

Early Morning Workshop 3

Room 332, Level 3

Summit 2, Level 3

Summit 2, Level 3

12:00 - 18:30

07:30 - 08:30

07:30 - 08:30

Hepatitis Elimination Symposium

Early Morning Workshop 2

Early Morning Workshop 4

Room 331, Level 3

Room 331, Level 3

Room 331, Level 3

13:00 - 18:00

 

 

 

08:30 - 18:00
Singapore Hepatology Conference
Summit 2, Level 3

 

 

 

09:00 - 18:00
Singapore Hepatology Conference
Summit 2, Level 3

Preceptorship Programme

Summit 2, Level 3

14:00 - 17:30

Ultrasound and Fibroscan Workshop 2

Room 332, Level 3

14:30 - 16:30

10:00 - 18:00
Science of HBV Cure
Room 331, Level 3

09:00 - 18:00
Science of HBV Cure
Room 331, Level 3

HBV cccDNA and Epigenetics Workshop

Room 333, Level 3

 

SHC 2018 – Conference Programme

 

FRIDAY 8 JUNE 2018 – SUMMIT 2

Time

Programme

08:30 – 10:00

8:30 – 8:40

Welcome remarks by the Conference Chairman and SHC partners

Combined

8:40 – 8:55

Opening Lecture: Landscape for viral hepatitis 

 

Patrick Marcellin, University of Paris, France

 

 

CHB Therapy

 

Chairs: Raj Reddy (USA), Tan Chee Kiat (Singapore)

 

8:55 – 9:10

HBV guidelines- Best practices for HBV therapy

 

Pietro Lampertico, University of Milan, Italy

 

9:10 – 9:25

Clinical advances in treatment of CHB

 

Man-Fung Yuen, The University of Hong Kong

 

9:25 – 9:40

Future Therapies for HBV

 

Stephen Locarnini, Victorian Infectious Diseases Reference Laboratory, Australia

 

9:40 – 10:00

Q&A

10:00 – 10:25

Tea Break

10:25 – 11:25

CHB Treatment Special Groups

Clinical

Chairs: Man-Fung Yuen (Hong Kong), Marc Bourliere (France), Irsan Hasan (Indonesia)

 

10:25 – 10:40

Immunosuppression induced reactivation of CHB

 

Kumar Visvanathan, St Vincent's Hospital, Australia

 

10:40 – 10:55

HBV and pregnancy

 

Sang Hoon Ahn, Yonsei University College of Medicine, Korea

 

10:55 – 11:10

CHB and advanced liver disease

 

Alexander Thompson, St. Vincent’s Hospital Melbourne , Australia

 

11:10 – 11:25

Round table discussion

11:25 – 12:30

Controversial Issues in CHB

Clinical

Chairs: Laurentius Lesmana (Indonesia),  Edward Gane (New Zealand)

 

11:25 – 11:40

Debate: Immunotolerant HBV – to treat or not?

 

·         To Treat: Pietro Lampertico, University of Milan, Italy

 

·         Not to treat: Teerha Piratvisuth, Prince of Songkla University, Thailand

 

11:40 – 11:55

Can treatment of CHB prevent HCC?

 

Sang Hoon Ahn, Yonsei University College of Medicine, Korea

 

11:55 – 12:30

Round table discussion

12:30 – 14:00

HBV-HCC Lunch Case Discussion

Clinical

Moderator: Guan Huei Lee (Singapore)

 

Panelists: Man-Fung Yuen (Hong Kong),  Robert Gish (USA) , Pei-Jer Chen (Taiwan) , Kwang-Hyub Han (Korea) , Tan Chee Kiat (Singapore)

14:00 - 15:30

Advanced Liver Disease Symposium

Clinical

Chairs: Teerha Piratvisuth (Thailand), Tan Soek Siam (Malaysia), Kyaw Soe Tun (Myanmar)

 

14:00 – 14:15

Update on management of liver cirrhosis, and  preventing complications

 

Raj Reddy, University of Pennsylvania, USA

 

14:15 – 14:30

Regression of liver cirrhosis: when and who?

 

Robert Gish, Stanford University, USA

 

14:30 – 14:45

Acute on Chronic Liver Failure

 

Yogesh  Chawla, Post Graduate Institute of Medical Education and Research, India

 

14:45 – 15:00

Diuretic resistant ascites

 

Marc Bourliere, Saint Joseph Hospital, France

 

15:00 – 15:15

Recent Developments in Liver Transplantation

 

Paul Kwo, Stanford University, USA

 

15:15 – 15:30

Round table discussion

15:30 - 15:45

Tea Break

15:45 - 17:30

Non-Alcoholic Fatty Liver Disease Symposium

Clinical

Chairs: Yock Young Dan (Singapore), George Goh (Singapore)

 

15:45 – 16:00

Pathophysiology and risk factors for NAFLD

 

Chan Wah Kheong, University of Malaya Medical Centre, Malaysia

 

16:00 – 16:15

Asian Prevalence of NAFLD

 

Chun-Jen Liu, National Taiwan University College of Medicine, Taiwan

 

16:15 – 16:30

Dietary manipulation in NAFLD & NASH

 

George Goh, Singapore General Hospital

 

16:30 – 16:45

Current management of NASH

 

Yock Young Dan, National University of Singapore

 

16:45 – 17:00

Therapeutic advances in NAFLD

 

Vlad Ratziu, Hôpital Pitié-Salpêtrière Medical School, France

 

17:00 – 17:30

Discussion Forum

 

End of day 1

     

SATURDAY 9 JUNE 2018 – SUMMIT 2

Time

Programme

 09:00 – 10:45

HCV Management

Clinical

Chair:  Khin Maung Win (Myanmar), Tan Soek Siam (Malaysia), Yang Wei Lyn (Singapore)

 

9:00 – 9:15

HCV Therapy: Is there still a role for personalised treatment of HCV?

 

Paul Kwo, Stanford University, USA

 

9:15 – 9:30

HCV co-infected with HBV

 

Chun-Jen Liu, National Taiwan University College of Medicine, Taiwan

 

9:30 – 9:45

DAA Treatment failures and resistance:

 

Marc Bourliere, Saint Joseph Hospital, France

 

9:45 – 10:00

Difficult to treat patients: CKD

 

Edward Gane, University of Auckland, New Zealand

 

10:00 - 10:30

Debate: Patients with decompensated liver disease should be transplanted first before treatment

 

·         For : Raj Reddy, University of Pennsylvania, USA

 

·         Against : Marc Bourliere, Saint Joseph Hospital, France

 

10:30 - 10:45

Round table Discussion

10:45 – 11:00

Tea Break

11:00 – 12:15

Hot Topics in Hepatology Symposium

Clinical

Chairs: Rino Gani (Indonesia)

 

11:00– 11:15

Non-invasive / invasive diagnosis of liver  fibrosis

 

Vlad Ratziu, Hôpital Pitié-Salpêtrière Medical School, France

 

11:15 – 11:30

New Treatments for Autoimmune and Cholesteric Liver Disease

 

Robert Gish, Stanford University, USA

 

11:30 – 11:45

The liver and the microbiome

 

Jonathan Lee, NUHS, Singapore

 

11:45 – 12:00

Stem cell therapy for liver disease

 

Yock Young Dan, National University of Singapore

 

12:00 – 12:15

Round table discussion

12:15– 14:00

HCV-NASH Lunch Case Discussion 

Clinical

Moderator: Dan Yock Young (Singapore)

 

Panelists:  Teerha Piratvisuth (Thailand) , Samir Shah (India) , Vlad Ratziu (France)

Marc Bourliere (France)

14:00 – 15:15

HCC Symposium Part 1

Clinical

Chairs: Tan Chee Kiat (Singapore),  Kwang-Hyub Han (Korea)

 

14:00 – 14:15

Mechanisms of carcinogenesis and prevention of HCC

 

Peter Galle, University Medical Center, Germany

 

14:15 – 14:30

Advances in biomarkers of HCC

 

Pei-Jer Chen, National Taiwan University Hospital, Taiwan

 

14:30 – 14:45

Pushing the limits for surgery in HCC?

 

Alfred Kow, NUHS, Singapore

 

14:45 – 15:00

Locoregional therapy for HCC

 

Kwang-Hyub Han, Yonsei University College of Medicine, Korea

 

15:00 – 15:15

Q&A

15:15 – 15:30

Tea Break

15:30 – 16:45

HCC Symposium Part 2

Clinical

Chairs: Tan Chee Kiat (Singapore),  Chee Cheng Ean (Singapore)

 

15:30 – 16:00

Debate: Management of HCC

 

·         Western perspective   Peter Galle, University Medical Center, Germany   

 

·         Eastern perspective Pierce Chow, National Cancer Centre Singapore 

 

16:00 – 16:15

Advances in Molecular targeted therapy for HCC

 

Goh Boon Cher, National University Cancer Institute, Singapore

 

16:15 – 16:30

Immunotherapy for HCC: the next big thing?

 

Stephen Chan, Chinese University of Hong Kong

16:30 – 17:45

The future of Systemic Therapies Forum

Clinical

Moderator Chee Cheng Ean (Singapore)

 

16:30 – 17:45

Panelists: Peter Galle (Germany), Pei-Jer Chen (Taiwan), Kwang-Hyub Han (Korea), Pierre Chow (Singapore), Goh Boon Cher (Singapore) , Stephen Chan (Hong Kong)

 

17:45

Conclusion